# Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

> **NCT03117933** · PHASE2 · COMPLETED · sponsor: **University of Oxford** · enrollment: 139 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Cediranib
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03117933
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-09
- **Primary completion:** 2021-03-12
- **Final completion:** 2023-12-31
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2024-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03117933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03117933, "Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03117933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*